Cyclin Dependent Kinase (CDK) Inhibitors Market 2022-2028

The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a substantial CAGR during the forecast period. One of the major factors driving the CDK inhibitors market is the rising prevalence of cancer across the globe. According to the World Health Organization (WHO), globally around 10 million deaths were reported which were caused due to cancer in 2020. In addition, the presence of a robust clinical pipeline due to the high demand for novel drugs and therapies is another factor propelling the growth of the market. Thus, market players are inclined toward launching novel CDK inhibitors to cater to the rising demand. For instance, in August 2020, ARC Therapeutic developed CDK inhibitors for treating advanced and resistant cancers. Currently, three CDK4/6 inhibitors including drugs such as palbociclib, ribociclib, and abemaciclib have been approved for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer by USFDA.

The global cyclin dependent kinase (CDK) inhibitors market is segmented based on the type, administration, and application. Based on the type, the market is segmented into specific inhibitors, non-specific or broad-range inhibitors, and multiple target inhibitors. Based on the administration, the market is sub-segmented into the nasal, oral, intravenous, and intramuscular. Based on application, the market is sub-segmented into breast cancer, lymphoma, multiple myeloma, ovarian cancer, and others. Among the administration segment, the oral sub-segment is expected to hold a considerable market share of the CDK inhibitors market over the forecast period, owing to the rising various R&D activities. For instance, in October 2021, the USFDA approved Verzenio in combination with endocrine therapy. Verzenio had been developed by Eli Lilly and Co. for treating HR+ HER2- early breast cancer. It is a non-chemotherapy oral tablet.

Geographically the global cyclin dependent kinase (CDK) inhibitors market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Among all the regions, North America is expected to hold a prominent share of the CDK inhibitors market during the forecast period, followed by Europe. The primary factor contributing to the regional growth includes the rising prevalence of cancer in the countries such as the US and Canada. According to the Canadian Cancer Society, in 2021, approximately 46% of the total Canadian population were diagnosed with cancer. Lung, breast, prostate, colorectal cancers are expected to remain the most commonly diagnosed cancer.

The major companies serving the global cyclin dependent kinase (CDK) inhibitors market include Beta Pharma, Inc., Eli Lilly & Co., FLX Bio, Inc., G1 Therapeutics Inc., Novartis Pharma AG, and Pfizer Inc., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in July 2021, PilmoSIM Therapeutics strategically collaborated with investigators from National Jewish Health and Brown University for the clinical development of PT001. To provide curative treatment, this drug targets multiple responsible pathways in PAH.

Research Methodology

The market study of the global cyclin dependent kinase (CDK) inhibitors market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The publisher's team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the publisher's analysts to derive the closest possible figures without any major deviations in the actual number. the publisher's analystss try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of the market size, and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

• Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Type.
• Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Administration.
• Global Cyclin Dependent Kinase (CDK) Inhibitors Market Research and Analysis by Application.

The Report Covers

• Comprehensive research methodology of the global cyclin dependent kinase (CDK) inhibitors market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global cyclin dependent kinase (CDK) inhibitors market.
• Insights about market determinants that are stimulating the global cyclin dependent kinase (CDK) inhibitors market.
• Detailed and extensive market segments with the regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.